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Abstract 
Background: Several cellular functions relate to ion-channels activity. Physiologically relevant chains of events lead-
ing to angiogenesis, cell cycle and different forms of cell death, require transmembrane voltage control. We hypothe-
sized that the unordered angiogenesis occurring in solid cancers and vascular malformations might associate, at least 
in part, to ion-transport alteration.
Methods: The expression level of several ion-channels was analyzed in human solid tumor biopsies. Expression of 
90 genes coding for ion-channels related proteins was investigated within the Oncomine database, in 25 independ-
ent patients-datasets referring to five histologically-different solid tumors (namely, bladder cancer, glioblastoma, 
melanoma, breast invasive-ductal cancer, lung carcinoma), in a total of 3673 patients (674 control-samples and 2999 
cancer-samples). Furthermore, the ion-channel activity was directly assessed by measuring in vivo the electrical sym-
pathetic skin responses (SSR) on the skin of 14 patients affected by the flat port-wine stains vascular malformation, i.e., 
a non-tumor vascular malformation clinical model.
Results: Several ion-channels showed significantly increased expression in tumors (p < 0.0005); nine genes (namely, 
CACNA1D, FXYD3, FXYD5, HTR3A, KCNE3, KCNE4, KCNN4, CLIC1, TRPM3) showed such significant modification in at 
least half of datasets investigated for each cancer type. Moreover, in vivo analyses in flat port-wine stains patients 
showed a significantly reduced SSR in the affected skin as compared to the contralateral healthy skin (p < 0.05), in 
both latency and amplitude measurements.
Conclusions: All together these data identify ion-channel genes showing significantly modified expression in 
different tumors and cancer-vessels, and indicate a relevant electrophysiological alteration in human vascular mal-
formations. Such data suggest a possible role and a potential diagnostic application of the ion–electron transport in 
vascular disorders underlying tumor neo-angiogenesis and vascular malformations.
Keywords: Cancer, Ion-channels, Autonomic nervous system, Sympathetic skin response, SSR, Flat port-wine stains
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Several key cellular functions are related to transmem-
brane potentials and lie under the control of ion chan-
nels, pumps and gap junction complexes. Controlling 
transmembrane voltage represents a fundamental pro-
cess in many physiologically relevant steps, includ-
ing cell cycle progression [1] and different forms of cell 
death [2, 3]. Over expression or increased activity of ion 
channels has been demonstrated as a response to mito-
gens exposure [4–6]. Several studies show a direct link 
between the transmembrane ion flow and carcinogenesis 
[7, 8]. However, as pointed out [9], the role membrane 
potential plays in the pathogenesis of several disorders, 
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membrane de-polarization has a pivotal role at different 
stages of cell cycle progression and in various cell types 
[9]. Namely, endothelial cells hyper-polarization has 
been shown to contribute to cell division arrest [10], and 
channels are known to control migratory cellular prop-
erties in wound healing [11]. Further, Ca2+, K+ and Cl− 
channels are essential regulators of cell proliferation and 
cancer development [12–16]. As recently further dem-
onstrated, several ion-channels are directly involved in 
controlling tumor—[17] as well as non-tumor angiogen-
esis [18]. Expression and activity of TRPV4 channel have 
been found suppressed in tumor endothelium [19], and 
its activation has been found to normalize tumor vessels 
[20]; inhibiting Cl− channel activity has anti-angiogenesis 
and anti-glioma properties [21]; finally, human voltage-
dependent K+ channel has been found associated with 
cancer aggressiveness and angiogenesis [22]. Therefore, 
ion-channels play a fundamental role in cancer progres-
sion as well as in angiogenesis.
Flat port-wine stains are non-tumor malformations of 
the skin capillaries [23]. Cutaneous capillary malforma-
tions are usually isolated finding. However, they may 
occasionally coexist with cerebral or ocular vascular mal-
formations, constituting the rare sporadic neurocutane-
ous Sturge-Weber syndrome (SWS) affecting the cephalic 
microvasculature, or may represent signs of more aggres-
sive vascular malformations or even vascular tumors.
The sympathetic skin response (SSR) is an alteration 
in skin electrical potential evoked by strong stimuli; it 
consists of a multineuronal reflex activated by a variety 
of afferent inputs where the efferent branches involve 
sympathetic sudomotor fibers. The electrodermal activ-
ity reflects sympathetic cholinergic sudomotor function 
which induces changes in skin resistance to electrical 
conduction. The response is mediated by ions flux via 
activation of receptor-coupled Ca2+, Cl− and K+ chan-
nels [24]. Since SSR reflects peripheral C fibers activity, 
it is considered a reliable quantitative measure of sym-
pathetic function and dysfunction as well as in polyneu-
ropathies and dysautonomic disorders [25–27].
We have previously shown novel serum markers able 
to indicate cardiovascular diseases, [28, 29] as well as 
soluble factors able to affect angiogenesis [30] and to dis-
criminate infantile hemangioma from more aggressive 
vascular malformations or tumors [31]. We also investi-
gated novel molecular markers of melanoma set-up and 
progression [32].
In the present study, we further addressed the issue 
of altered angiogenesis in tumor and non-tumor condi-
tions. The expression level of 90 ion-channel genes was 
investigated in five different solid tumors, having a dif-
ferent histological origin. The expression level of several 
ion-channels genes was found to be strongly modified; 
we thus hypothesized that ion-transport may represent 
a measurable sign of the altered underlying angiogenesis. 
We, therefore, measured in  vivo the ion-channel func-
tion in a human vascular malformation model, namely 
flat port-wine stains, as a model to test electrical-stimuli 
transport in a human vascular disorder accepted by the 
Ethic Committee.
Methods
Ion‑channel gene expression investigation
Gene expression levels were investigated by accessing 
human cancer datasets available at Oncomine (http://
www.oncomine.org). The current Oncomine version 
contains several hundred different patients-datasets, 
referring to tumors biopsies obtained from almost any 
histological source; unfortunately vascular tumors (such 
as hemangioma, angiomas, hemangioendothelioma, 
angiosarcoma) are lacking from such database. In the 
current study 25, independent datasets from histologi-
cally different solid tumors were investigated, namely, 
bladder cancer, glioblastoma, melanoma, breast cancer, 
lung adenocarcinoma, as indicated in details in Table 1.
Table 2 reports the detailed list of the 90 ion-channels 
and ion-channel related genes investigated in the pre-
sent study. Briefly, different members were selected from 
21 channel families, namely: amiloride-sensitive cation 
channels, calcium Channels voltage-dependent, cation 
channels sperm associated, FXYD domain containing ion 
transport regulators, gamma-aminobutyric acid (GABA) 
receptors, glutamate receptors ionotropic, potassium 
channels voltage gated subfamily, cholinergic receptors 
(Nicotinic), chloride channels, cyclic nucleotide gated 
channels, glutamate Receptors, sodium leak channels, 
purinergic receptors P2X, sodium-hydrogen exchanger 
regulatory factor 4, regulatory solute carrier proteins, 
sodium channels, glucose activated Ion channels, two 
pore segment channels, transient receptor potential cat-
ion channels, zinc activated ion channels, aquaporins.
Expression of such 90 genes was evaluated in oncomine 
database by setting “cancer vs. normal analysis” and 
choosing as cancer type: “superficial bladder cancer” 
within the bladder cancer group, “glioblastoma” within 
the brain and CNS cancer group, “breast invasive 
ductal carcinoma” within the breast cancer group, “lung 
adenocarcinoma” within the lung cancer group, and 
“melanoma”.
Expression fold change (cancer vs. normal samples) and 
p values were reported for each analysis. Gene expres-
sion in tissue biopsies from 3673 patients was analyzed. 
Namely, 674 control-samples and 2999 cancer-samples 
were investigated.
Two additional datasets were identified and investi-
gated within GEO database from NCBI (http://www.
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ncbi.nlm.nih.gov/gds), namely GSE41614 and GSE44115. 
Such datasets specifically refer to the vessels component 
within cancer samples; they were analyzed by means of 
the GEO2R interface available at the http://www.ncbi.
nlm.nih.gov/gds site.
Patients recruitment
Several reports indicate that direct electrical stimulation 
may affect cell proliferation and dissemination in onco-
logical setups and may induce other physiological effects 
[33–39]. Thus a clinical-study involving any electrical 
stimulation in cancer patients would be not acceptable by 
the Ethic Committee, according to the articles n. 14 and 
n. 16 of the Helsinki declaration on biomedical studies 
involving human patients, and to the article n. 16 of the 
Oviedo Convention.
For such reasons we submitted to the Ethic Committee 
the request to authorize the in vivo investigation in non-
tumor patients showing a pathological condition resem-
bling, at least in part, the tumor neo-angiogenesis. Such 
request was authorized by the Ethic Committee and this 
explains way we investigated the SSR in angioma patients.
Fourteen patients (six males and eight females) affected 
by cutaneous flat port-wine stains were recruited at IDI-
IRCCS, Rome. The study was approved by the institu-
tional review board of IDI-IRCCS Hospital, Rome (IDI 
Ethic Committee 2011, n. 363). Patients with flat port-
wine stains diagnosis (age 18–70  years) undergoing no 
Table 1 Tumors types, datasets names, patients numerosity and  reference of  each dataset investigated in  the present 
study, from oncomine database (http://www.oncomine.org)
Tumor type and dataset name No  of control samples No  of cancer samples References n.
Superficial bladder cancer
 1 Dyrskjot dataset 14 28 [86]
 2 Lee dataset 68 126 [87]
 3 Sanchez dataset 48 28 [88]
 4 Blaveri dataset 2 25 [89]
Glioblastoma
 5 Lee dataset 3 78 [90]
 6 Bredel dataset 4 26 [91]
 7 Sun dataset 23 81 [92]
 8 Murat dataset 4 80 [93]
Melanoma
 9 Talantov dataset 7 45 [94]
 10 Riker dataset 5 14 [95]
 11 Critchley dataset 23 23 [96]
 12 Haqq dataset 3 23 [97]
Breast invasive ductal cancer
 13 Ma dataset 28 18 [98]
 14 Curtis dataset 144 1556 [99]
 15 Radvanji dataset 5 26 [100]
 16 Turashvi dataset 20 5 [101]
 17 Zhao dataset 4 154 [102]
Lung adenocarcinoma
 18 Bhattacharjee dataset 17 139 [103]
 19 Beer dataset 10 86 [104]
 20 Stearman dataset 19 20 [105]
 21 Hou dataset 65 45 [106]
 22 Okayama dataset 20 226 [107]
 23 Selamat dataset 58 58 [108]
 24 Landi dataset 49 58 [109]
 25 Su dataset 31 31 [110]
Totals 674 2999
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Table 2 Complete list of ion-channel genes and ion-channel related genes investigated
Gene family Gene name Whole gene name
(A) Amiloride-sensitive cation channel
1 ACCN1 Amiloride-sensitive cation channel 1
2 ACCN2 Amiloride-sensitive cation channel 2
3 ACCN3 Amiloride-sensitive cation channel 3
4 ACCN4 Amiloride-sensitive cation channel 4
(B) Calcium channel, voltage-dependent
5 CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A Subunit
6 CACNA1B Calcium channel, voltage-dependent, N type, alpha 1B Subunit
7 CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C Subunit
8 CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D Subunit
(C) Cation channel, sperm associated
9 CATSPER1 Cation channel, sperm associated 1
10 CATSPER2 Cation channel, sperm associated 2
11 CATSPER3 Cation channel, sperm associated 3
12 CATSPER4 Cation channel, sperm associated 4
(D) FXYD domain containing ion transport regulator
13 FXYD1 FXYD domain containing ion transport regulator 1
14 FXYD2 FXYD domain containing ion transport regulator 2
15 FXYD3 FXYD domain containing ion transport regulator 3
16 FXYD4 FXYD domain containing ion transport regulator 4
17 FXYD5 FXYD domain containing ion transport regulator 5
(E) Gamma-aminobutyric acid (GABA) A receptor
18 GABRA1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1
19 GABRB3 Gamma-aminobutyric acid (GABA) A receptor, beta 3
20 GABRP Gamma-aminobutyric acid (GABA) A receptor, Pi
(F) Glutamate receptor, ionotropic
21 GRIA1 Glutamate receptor, ionotropic, AMPA 1
22 GRIN2A Glutamate receptor, ionotropic, N-methyl d-aspartate 2A
23 HTR3A 5-Hydroxytryptamine (serotonin) receptor 3A, ionotropic
24 HTR3B 5-Hydroxytryptamine (serotonin) receptor 3B, ionotropic
(G) Potassium channel, voltage gated subfamily
25 KCNE3 Potassium channel, voltage gated subfam.E regulatory beta Sub. 3
26 KCNE4 Potassium channel, voltage gated subfam.E regulatory beta Sub. 4
27 KCNH2 Potassium channel, voltage gated Eag related subfamily H, 
member 2
28 KCNH1 Potassium channel, voltage gated Eag relat.subfam.H, Member 1
29 KCNJ11 Potassium channel, inwardly rectifying subfamily J, member 11
30 KCNJ12 Potassium channel, inwardly rectifying subfamily J, member 12
31 KCNMA1 Potassium channel, calcium activated large conductance 
subfam.M alpha, member 1
32 KCNMB2 Potassium channel subfamily M regulatory beta subunit 2
33 KCNMB4 Potassium channel subfamily M regulatory beta subunit 4
34 KCNQ1 Potassium channel, voltage gated KQT-Like Subfam. Q, Member 1
35 KCNRG Potassium channel regulator, protein CLLD4
36 KCNV1 Potassium channel, voltage gated modifier subfamily V, Member 1
37 KCNN1 Potassium channel, calcium activated intermediate/small con-
ductance subfamily N alpha, member 1
38 KCNN2 Potassium channel, calcium activated intermediate/small con-
ductance subfamily N alpha, member 2
39 KCNN3 Potassium channel, calcium activated intermediate/small con-
ductance subfamily N alpha, member 3
Page 5 of 15Biasiotta et al. J Transl Med  (2016) 14:285 
Table 2 continued
Gene family Gene name Whole gene name
40 KCNN4 Potassium channel, calcium activated intermediate/small con-
ductance subfamily N alpha, member 4
(H) Cholinergic receptor, nicotinic
41 CHRNA1 Cholinergic receptor, nicotinic, alpha 1 (muscle)
42 CHRNA2 Cholinergic receptor, nicotinic, alpha 2 (neuronal)
43 CHRNA3 Cholinergic receptor, nicotinic, alpha 3 (neuronal)
44 CHRNA5 Cholinergic receptor, nicotinic, alpha 5 (neuronal)
(I) Chloride channel
45 CFTR Cystic fibrosis transmembrane conductance regulator
46 BEST1 Bestrophin 1
47 CLCN1 Chloride channel 1, skeletal muscle (CIC-1)
48 CLCN5 Chloride channel, voltage-sensitive 5 (CIC-5)
49 CLIC1 Chloride intracellular channel 1
50 CLIC4 Chloride intracellular channel 4
(L) Cyclic nucleotide gated channel
51 CNGB3 Cyclic nucleotide gated channel beta 3
(M) Glutamate receptor
52 GRID1 Glutamate receptor, ionotropic, delta 1
53 GRID2 Glutamate receptor, ionotropic, delta 2
(N) Sodium leak channel
54 NALCN Sodium leak channel, non selective
(O) Purinergic receptor P2X
55 P2RX1 Purinergic receptor P2X, ligand gated ion channel, 1
56 P2RX2 Purinergic receptor P2X, ligand gated ion channel, 2
57 P2RX3 Purinergic receptor P2X, ligand gated ion channel, 3
58 P2RX4 Purinergic receptor P2X, ligand gated ion channel, 4
59 P2RX6 Purinergic receptor P2X, ligand gated ion channel, 6
60 P2RX7 Purinergic receptor P2X, ligand gated ion channel, 7
(P) Sodium-hydrogen exchanger regulatory factor 4
61 PDZD3 PDZ domain containing 3
(Q) Regulatory solute carrier protein
62 RSC1A1 Regulatory solute carrier protein, family 1, member 1
(R) Sodium channel
63 SCN1A Sodium channel, voltage gated, type I alpha subunit
64 SCN2A Sodium channel, voltage gated, type II alpha subunit
65 SCN3A Sodium channel, voltage gated, type III alpha subunit
66 SCN4A Sodium channel, voltage gated, type IV alpha subunit
67 SCN5A Sodium channel, voltage gated, type V alpha subunit
68 SCN8A Sodium channel, voltage gated, type VIII alpha subunit
(S) Glucose activated ion channel
69 SLC5A4 Solute carrier family 5 (glucose activated ion channel)
(T) Two pore segment channel
70 TPCN1 Two pore segment channel 1
71 TPCN2 Two pore segment channel 2
(W) Transient receptor potential cation channel
72 TRPC1 Transient recep. potential cation channel, subfamily C, member 1
73 TRPC2 Transient recep. potential cation channel, subfamily C, member 2
74 TRPC3 Transient recep. potential cation channel, subfamily C, member 3
75 TRPC4 Transient recep. potential cation channel, subfamily C, member 4
76 TRPM1 Transient recep. potential cation channel, subfamily M, member 1
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treatment of any type were consecutively recruited. 
Patients did not show systemic or neurological disorders 
nor obvious psychological problems. Physical general and 
neurological examination were normal in all cases. The 
average lesion was about 25 cm × 10 cm, typically a por-
tion of the limb. All patients signed an informed consent 
to participate in the study.
Sympathetic skin responses SSR recording
SSR study was carried out according to the techni-
cal standards of the International Federation of Clinical 
Neurophysiology [40]. During the test, subjects were kept 
relaxed with comfortable light and temperature (26–
28 °C); the test was started after 5 min of previous adap-
tation. The apparatus used was an electromyography and 
evoked potential equipment (MedelecSynergy, Viasys 
Healthcare, Madison WI USA). Recording electrodes 
consisted of a pair of superficial electrodes: recording 
was carried out on the glabrous skin on the flat port-wine 
stain, and the reference was placed 2 cm away from the 
lesion. The ground electrode was proximal to the record-
ing electrodes. Electrical stimulation was applied through 
superficial electrodes over the right median nerve. The 
stimulus was strong but tolerable (not noxious). The 
electrical stimulus was applied four times at irregular 
intervals of 30–60  s (stimulus duration: 0.1  ms; inten-
sity: 80  mA) to avoid habituation, and SSR waves were 
obtained. SSR recordings were carried out in quadrupli-
cates at the angiomas lesion sites and onto a contralateral 
healthy skin region in each patient.
The amplifier bandwidth was 0.1–100  Hz. Responses 
were recorded on the skin with an impedance <5 kΩ. The 
mean latency and peak-to-peak amplitude were calcu-
lated and used for the following analyses.
Statistical analysis
For gene expression data, the statistically significant 
threshold originally set at p  =  0.05 was then corrected 
according to the Bonferroni correction for multiple com-
parisons, to take into account the multiple comparisons 
carried out. Therefore, the final corrected threshold was 
set at p < 0.0005 (value obtained from 0.05/90 compari-
sons, for each investigated dataset).
The expression level of any given gene was considered 
to be significantly altered vs control when the significant 
p value was matched in at least half—or in at least 1—of 
the specific databases investigated for each tumor type. 
Namely, regarding the “at least half datasets” stringency 
level, the significant p value had to be matched in at least 
2 datasets out of the 4 investigated for bladder cancer; in 
at least 2 datasets out of the 4 studied for glioblastoma; in 
at least 2 datasets out of the 4 examined for melanoma; 
in at least 3 datasets out of the 5 investigated for invasive 
ductal breast carcinoma; in at least 4 datasets out of the 8 
investigated for lung adenocarcinoma.
SSR was recorded four consecutive times for each 
patient on the diseased skin and four consecutive times 
on the healthy contralateral skin. Mean ±  SE was com-
puted; mean latency and mean peak-to-peak amplitude 
recorded at the diseased-skin level were compared to 
measures obtained on the contralateral healthy control 
site. Paired t Student test was carried out, and statistical 
significance was set at p  <  0.05. Normal distribution of 
SSR data was tested according to the D’Agostino-Pearson 
Table 2 continued
Gene family Gene name Whole gene name
77 TRPM2 Transient recep. potential cation channel, subfamily M, member 2
78 TRPM3 Transient recep. potential cation channel, subfamily M, member 3
79 TRPM4 Transient recep. potential cation channel, subfamily M, member 4
80 TRPM7 Transient recep. potential cation channel, subfamily M, member 7
81 TRPV1 Transient recep. potential cation channel, subfamily V, Member 1
82 TRPV2 Transient recep. potential cation channel, subfamily V, member 2
83 TRPV3 Transient recep. potential cation channel, subfamily V, member 3
84 TRPV4 Transient recep. potential cation channel, subfamily V, member 4
(Y) Zinc activated ion channel
85 ZACN Zinc activated ligand-gated ion channel
(Z) Acquaporins
86 AQP1 Aquaporin 1
87 AQP2 Aquaporin 2
88 AQP3 Aquaporin 3
89 AQP4 Aquaporin 4
90 AQP5 Aquaporin 5
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test and carried out by the GraphPad software. Data with 
normal distribution were analyzed with the paired t test, 
while data with a not-normal distribution were analyzed 
with the non-parametric Wilcoxon match-paired signed 
ranked test.
Results
Expression level of ion‑channels genes in tumors
The expression level of 90 ion-channels and ion-channels 
related genes (see Table 2 for the complete list) was ana-
lyzed in 3673 human biopsies of 5 histologically different 
solid tumors, namely: superficial bladder cancer, glio-
blastoma, melanoma, invasive ductal breast cancer, lung 
adenocarcinoma, as reported in Table 1 in more details.
Table  3 indicates the ion-channel families showing a 
significantly altered expression (p  <  0.0005). For each 
cancer type, two columns are presented: the left-hand 
column (lighten) reports genes indicating a significantly 
modified expression in at least 1—or less than half-of 
the investigated datasets. The right-hand column of each 
tumor type (shadowed) reports in bold all genes show-
ing a significantly modified expression in at least half of 
the examined datasets (see criteria detailed in “Methods” 
section). All genes matching the shadowed columns cri-
teria were found overexpressed. More in detail:
  • Within the calcium channel, voltage-dependent fam-
ily, expression of CACNAD1 gene was found signifi-
cantly modified in superficial bladder cancer data-
sets, namely in Dyrskjot dataset (p = 4 × 10−6) and 
in Sanchez dataset (p =  5 ×  10−8), with an average 
3.7-fold increase vs. ctrls;
  • Within the FXYD domain containing ion transport 
regulator family, expression of FXYD3 gene was 
found significantly modified in bladder cancer (Dys-
kjot dataset, p = 1 × 10−6, Lee dataset, p = 3 × 10−6 
and Sanchez dataset, p =  6 ×  10−21) with an aver-
age 3.3-fold increase vs. ctrls. Furthermore, FXYD5 
gene expression was found significantly modified in 
glioblastoma (in Lee dataset, p  =  2  ×  10−5 and in 
Sun dataset, p = 1 × 10−11) with an average 2.5-fold 
increase vs. ctrls;
  • Within the glutamate receptor, ionotropic family, 
expression of HTR3A gene was found significantly 
modified in 5 lung carcinoma datasets, namely 
in Beer dataset (p  =  3  ×  10−8), in Hou dataset 
(p = 7 × 10−6), in Okayama dataset (p = 2 × 10−13), 
in Selamat dataset (p = 1 × 10−8), and in Landi data-
set (p = 8 × 10−6) with an average 5.08 fold increase 
vs ctrls;
  • Within the potassium channel, voltage gated fam-
ily, expression of three genes was found significantly 
modified in two cancer types. Namely, KCNE3 and 
KCNE4 genes are modified in glioblastoma data-
sets. KCNE3 shows an average 5.3-fold increase vs. 
ctrls (in Lee dataset, p = 3 × 10−10 and in Sun data-
set, 5  ×  10−9). KCNE4 shows an average 2.9-fold 
increase vs ctrls in Lee dataset (p =  1 ×  10−8) and 
in Sun dataset (p =  1 ×  10−13). KCNN4 was found 
altered in nearly all lung carcinoma datasets, namely 
in Bhattacharjee dataset (p  =  1  ×  10−6), Stearman 
dataset (p = 3 × 10−7), Hou dataset (p = 3 × 10−9), 
Okayama dataset (p  =  1  ×  10−8), Selamat dataset 
(p = 2 × 10−14), Landi dataset (p = 2 × 10−17) and 
in Su dataset (p = 6 × 10−8) with an average 3.6-fold 
increase vs ctrls;
  • Within the chloride channel family, expression of 
CLIC1 gene was found significantly modified in blad-
der cancer (in Lee dataset, p = 8 × 10−8 and Sanchez 
dataset, p  =  3  ×  10−5) with an average 1.5-fold 
increase vs. ctrls. CLIC1 is also significantly modified 
in glioblastoma (in Bredel dataset, p = 3 × 10−7 and 
Sun dataset, p = 2 × 10−23) with an average 5.7-fold 
increase vs. ctrls;
  • Within the transient receptor potential cation chan-
nel family, expression of TRPM3 gene is altered in 
glioblastoma, i.e., in the Lee dataset (p = 5 × 10−5) 
and in the Sun dataset (p = 2 × 10−5) with an aver-
age 2.3-fold increase vs. ctrls.
Within the shadowed columns, glioblastoma appears to 
have the highest number of modified ion-channel genes 
(namely: FXYD5, KCNE3, KCNE4, CLIC1, TRPM3).
Melanoma and breast cancer show no genes in the 
shadowed columns. However, within the lighten col-
umns, breast invasive ductal cancer and melanoma show 
significantly modified ion-channel genes from 13 families 
and 6 families, respectively.
SSR recording in flat port‑wine stains patients
The above reported analyses demonstrated that the 
expression level of several ion-channels is significantly 
altered in several human cancer biopsies. Such tumors 
are histological different. However, they all present an 
altered vascular tree, due to the tumor neo-angiogen-
esis. We hence hypothesized that vascular alterations 
observed in several different cancer types may harbor, 
at least to a certain extent, the observed ion-channels 
expression modifications. According to these findings, 
we hypothesized that measuring ion-channel transport 
may represent a non-invasive technique to investigate 
alterations in tumor- as well non-tumor altered angio-
genesis. In  vivo analysis of ion transport in a vascular 
malformation, the clinical model was carried out. In 
fact, measuring in  vivo ion-transport in tumor patients 
was considered ethically not acceptable; we were then 
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forced to identify a non-tumor clinical condition show-
ing clear vascular anomalies. The flat port-wine stains 
clinical model was approved by the Ethic Committee as 
a safe model to investigate Sympathetic Skin Responses 
and electrical signal transport, as the less invasive 
approach possible in the current study. SSR depends on 
Ca2+, K+, and Cl− channels found to be altered in Table 3. 
Therefore, 14 patients with flat port-wine stains diagnosis 
were consecutively recruited, namely eight female (mean 
age 27  years) and six male (mean age 29.1  years). SSR 
recordings were carried out in quadruplicates at the angi-
omas lesion sites and onto a contralateral healthy skin 
region in each patient. Statistical analysis was performed 
with paired tests as reported in Methods.
Table 3 Genes reported show a significantly altered expression in each cancer type
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Significance threshold: p < 0.0005 (see “Methods” section)
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Figure  1 shows the mean latency and means 
amplitude measured at diseased and healthy sites, 
expressed in mV. A strong and significant reduc-
tion in both latency and peak-to-peak amplitude sig-
nals was observed in the diseased site as compared 
to the healthy site, in the whole patients population. 
When a gender-specific analysis was carried out, both 
latency and amplitude were strongly reduced in female 
patients, while latency was reduced in male, although 
in a not-significant manner.
Ion channel expression in normal vessels as compared 
to tumor derived vessels
Data reported in Table 3 and in Fig. 1 led us to hypoth-
esize that ion channels genes may play a relevant role in 
cancers as well as in other pathological conditions of 
altered angiogenesis. To further support this hypothesis 
we investigated two human samples datasets available at 
GEO database. The first dataset (GSE41614) reports tran-
scriptional profiling of tumor-associated blood vessels in 
human invasive bladder cancer samples. In such dataset 
the expression data were obtained on laser capture micro-
dissected vessels isolated from normal bladder tissue or 
from tumor bladder tissues. Data from ten samples were 
analyzed, i.e., five normal samples vs five cancer samples.
The second dataset (GSE44115) reports gene expres-
sion data in OCT frozen human angiosarcoma compared 
to OCT frozen normal mesenchymal tissues. In this case 
18 angiosarcoma samples were compared to four controls 
(two from skeletal muscle normal uninvolved tissue and 
two pooled RNA from normal tissues).
Tables  4 and 5 report the gene name, the log2 fold 
change, the p values adjusted according to the Benjamini 
and Hochberg false discovery rate methods, and the rank 
position (according to the by p value). Several genes, 
within the top 250 genes most significantly regulated, 
belong to ion channels families, either in bladder cancer 
blood vessels (9 genes, Table 4) and in angiosarcoma ves-
sels (123 genes, Table 5). Such data indicate that several 
ion channels may play a key role in the vessels within 
cancer tissues.
Discussion
It is widely known that nerves and vessels follow similar 
anatomical paths. Often nerves and vessels show an over-
lapping anatomy with overlapping branches and ramifi-
cations. Several molecular factors are reported to control 
their respective patterns and growth in a coordinated 
manner [41], including semaphorin, netrin and slit [42], 
all strongly regulated by Ca2+, Na+, and Cl− channels 
[43, 44]. Thus, an architectural or functional modifica-
tion of the ones may affect the architecture or function 
of the others. We, therefore, argued that unordered angi-
ogenesis occurring in tumors and vascular malforma-
tions may associate to a corresponding unordered nerve 
formation and therefore to a measurable alteration of 
the electric stimulus transport. We hypothesized that (i) 
ion channels (which are known to regulate nerve- and 
Fig. 1 SSR recordings carried out in 14 flat port-wine stains patients. Both latency and amplitude signals were measured on the angioma site and 
the contralateral healthy site of each patient. A paired test was carried out according to “Methods” section. **indicates p < 0.01; *indicates p < 0.05
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vessel- formation) may show altered expression in 
tumors and (ii) SSR recording in vascular malformations 
patients may unreveal a clinical non-invasive sign of the 
unordered vessels formation.
The expression level of members of several ion-channel 
families was found significantly modified in histologically 
different human cancer biopsies, according to the meas-
ures reported in Oncomine database, in an almost 4000 
patients-vs-controls group. While several genes were 
found significantly modified (p < 0.0005) in at least one 
human dataset, we limit here the discussion to the genes 
reported in the shadowed columns of Table  3 selected 
according to highly stringent criteria, i.e. to the ion-chan-
nel genes found altered in at least half of the investigated 
databases of each tumor. We report in the current study 
that such genes show an increased expression in cancer 
vs. ctrls samples and have in most cases a definite role 
in vascular biology and/or cancer setup/progression or 
nervous system biology.
CACNA1D, a calcium related transporter gene, shows 
an average 3.75-fold increased expression in superfi-
cial bladder cancer datasets. No reports are present in 
Table 4 Ion channels genes most regulated in bladder cancer vessels vs control vessels
* According to the Benjamini and Hochberg false discovery rate method
Data from Geo dataset GSE41614, available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41614)
Rank position in the top 250 
(by p value)
Gene identifier Gene name Adjusted p value* log2 fold change
16th KCNC4 Potassium voltage-gated channel subfamily C mem-
ber 4
0.009 +0.507
42th KCNG4 Potassium voltage-gated channel modifier subfamily 
G member 4
0.01 +0.415
75th VDAC3 Voltage dependent anion channel 3 0.01 −1.511
90th CRACR2B Calcium release activated channel regulator 2B 0.01 +0.472
115th KCNS2 Potassium voltage-gated channel modifier subfamily 
S member 2
0.01 +0.637
153th SEC23B Sec23 homolog B, coat complex II component 
(involved in vesicle trafficking)
0.01 −0.566
173th CBARP CACN Beta subunit associated regulatory protein 0.01 +0.627
218th P2RX5 Purinergic receptor P2X 5 (ligand-gated ion channel) 0.01 +0.403
247th SCN2B Sodium voltage-gated channel beta subunit 2 0.02 +0.487
Table 5 Ion channels genes most regulated in angiosarcoma vs controls
* According to the Benjamini and Hochberg false discovery rate method
Data from Geo dataset GSE44115, available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44115)
Rank position in the top 
250 (by value)
Gene identifier Gene name Adjusted p value* log2 fold change
3th KCNJ16 Potassium voltage-gated channel subfamily J member 16 0.0000003 +6.673
41th CLCNKA Chloride voltage-gated channel Ka 0.001 +3.516
52th HCN2 Hyperpolarization activated cyclic nucleotide gated potas-
sium channel 2
0.001 +2.099
53th KCNQ2 Potassium voltage-gated channel subfamily Q member 2 0.001 +1.276
61th FXYD4 FXYD domain containing ion transport regulator 4 0.0009 +6.247
75th CRACR2B Calcium release activated channel regulator 2B 0.002 +1.117
104th AQP10 Aquaporin 10 0.004 +2.096
125th KCNJ15 Potassium voltage-gated channel subfamily J member 15 0.004 +3.203
147th KCNK12 Potassium two pore domain channel subfamily K member 
12
0.004 +2.008
153th FXYD2 FXYD domain containing ion transport regulator 2 0.005 +2.596
167th KCNJ1 Potassium voltage-gated channel subfamily J member 1 0.01 +3.369
250th AQP2 Aquaporin 2 0.01 +8.359
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literature referring CACNA1D direct link to bladder can-
cer. Nevertheless, some studies relate its expression- and 
methylation-level to prostate cancer [45, 46], indicating 
CACNA1D as a possible regulator of prostate cancer 
aggressiveness [47], or refer it to CNS disorders [48], dia-
betes [49] or calcium level within the vessels [50].
FXYD3 shows a 3.3 average fold increase expression 
in bladder cancer. It encodes a cell membrane protein 
regulating ion-pumps and ion-channels function and is 
known to have a role in tumor progression. Its activity 
is related to glucose and Cl− ions and has been indicated 
as a possible biomarker in bladder cancer [51, 52] as well 
as other cancers including breast [53], colorectal cancer 
[54], endometrial cancer [55] and intrahepatic cholangio-
carcinoma [56].
FXYD5 is a transmembrane auxiliary subunit of the 
Na+-K+-ATPase; it shows a 2.5-fold increase in glioblas-
toma. No direct link with glioblastoma has been reported 
to date, however it has been found up-regulated in ada-
mantinomatous craniopharyngiomas in children [57] 
and other members of the FXYD family are known to be 
associated with different cancer types such as urothelial 
carcinoma [58], esophageal squamous cell carcinoma 
[59] and cholangiocarcinoma [60]. FXYD channels are 
involved in the anti-oxidative stress in vascular smooth 
muscle, thus controlling the vascular tone [61] and blood 
pressure [62]. Most interestingly, expression of FXYD2 
and FXYD4 genes is modified in angiosarcoma vs control 
human samples (Table 5).
The expression of serotonin receptor HTR3A was 
found increased by fivefold in lung carcinoma; no direct 
link has been reported between HTR3A and lung adeno-
carcinoma, yet; however, nucleotide polymorphisms of 
this gene have been related to opioid- or nausea/vomiting 
signaling pathways in cancer patients [63] and to bowel 
syndrome [64]. HTR3 is the only ligand-gated ion chan-
nel among the serotonin receptors, and it has been asso-
ciated with neurological disorders such as depression 
[65] or schizophrenia [66]. Most interestingly about the 
current study, HTR3A acts as a ligand-gated ion channel 
neurotransmitter, and causes fast, depolarizing responses 
in neurons (http://www.genecards.org/cgi-bin/carddisp.
pl?gene=HTR3A). It is up-regulated in rosacea, i.e., a 
chronic inflammatory skin disease often showing telangi-
ectasias in the erythematotelangiectatic form (ETR) [67].
Within the potassium intermediate/small conduct-
ance calcium-activated channels, expression of 3 genes 
(namely KCNE3, KCNE4, KCNN4) has been found 
altered in the current study, namely in glioblastoma and 
lung adenocarcinoma. While no direct evidence relate 
KCNE3 or KCNE4 to glioblastoma, KCNE4 is most 
abundantly expressed in brain [68]; it exerts functions 
such as controlling the neuronal firing rate, the synaptic 
transmission [69] and the T-lymphocytes maturation 
[70] and it is known to regulate K-channels in vascular 
smooth muscle [71] and more in general neuronal excit-
ability. Furthermore, KCNN4 single-nucleotide polymor-
phisms have been related to myocardial infarction [72]. 
Most interestingly, KCNN4 has been linked to vascular 
cells proliferation [73]. Notably, expression of several 
potassium channels is modified in bladder cancer vessels 
vs controls (KCNC4, KCNG4, KCNS2, see Table 4) and 
in angiosarcoma vs controls (namely KCNJ16, KCNQ2, 
KCNJ15, KCNJ12, KCNJ1, see Table 5).
Within the Cl- intracellular channels, CLIC1 expres-
sion was found altered in bladder cancer and glioblas-
toma. CLIC1 has been previously found up-regulated in 
glioblastoma [74], it is involved in different tumors and 
acts as an oncogene in pancreatic cancer [75], and has 
been indicated as a possible cancer biomarker [76]. Inter-
estingly, CLIC1 has recently shown a key role in angio-
genesis control in combination with integrins [77, 78]. 
Interestingly, expression of one Cl− channel (namely 
CLCNKA) is strongly modified in angiosarcoma vs con-
trols (see Table 5).
Within the transient receptor potential cation chan-
nels, TRPM3 gene expression was found increased in 
glioblastoma by 2.3-fold. Its expression has been previ-
ously found increased in glioblastoma [79] and is known 
to exhibit mechanosensitivity contributing to vascular 
and cardiac functions [80].
SSR is under the direct control of Ca2+, K−, Cl− ion 
channels and strictly depends on the sympathetic auton-
omous nerve function. In the current study, several 
ion channels related to the Ca2+, K+, and Cl− have rel-
evant, and significantly increased expression in differ-
ent human cancers and SSR was found strongly altered 
in human vascular malformations. SSR has been previ-
ously indicated as a possible useful diagnostic technique 
in CNS pathologies [81, 82], as well as fibromyalgia [83] 
and diabetes [84]. Further, autonomic nerve develop-
ment and function has been recently shown to play a key 
role in prostate cancer progression [85]. Thus, given the 
known role of several ion channels in the tumor, nerve, 
and vascular biology, we hypothesize that the altered 
SSR observed in vascular skin malformations, and the 
observed altered ion-channel gene-expression in several 
tumors may represent phenomena related to the unor-
dered nerve- and vessel formation, common to tumor-
related and non-tumor-related vascular anomalies.
SSR recording gave more significant results in female 
while in male the trend was present but with no statisti-
cal significance. Such difference may be related to a dif-
ferent transport of electrical stimuli in the female skin, 
which appears evident at both healthy (white boxes 
in Fig.  1) and diseased sites (black boxes in Fig.  1), as 
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compared to male. A gender-related difference in the skin 
thickness may underlie, at least in part, such observation 
likely associated with the skin thickness and water reten-
tion induced by the menstrual phases and the hormonal 
status in females.
In conclusion, data reported in the current study 
allowed us to conclude that ion-channel expression and 
function may be strongly affected in pathological condi-
tions where vessels’ (and nerves’) architecture is altered. 
SSR measurement may thus represent a non-invasive 
useful tool to investigate vascular skin alterations in both 
tumor and non-tumor conditions.
Conclusions
The present study reports for the first time a detailed 
analysis of the expression level of 90 ion-channel genes in 
3673 biopsies form humans affected by solid tumors and 
from healthy controls. At least ten genes from different 
ion-channels families were found firmly and significantly 
up-regulated in histologically different tumors having in 
common the underlying unordered tumor neo-angio-
genesis (Table 3). Moreover, expression of at least 20 ion 
channels has been found to be strongly modified in can-
cer associated vessels vs controls (Tables 4, 5). The sym-
pathetic skin responses (SSR), an electrical feature closely 
related to the ion-channels activity, was then measured 
in  vivo and was found strongly modified in the skin of 
patients affected by the flat port-wine stains vascular 
malformation. The present study indicates that modified 
expression and activity of ion channels is likely related to 
vascular alteration, in both tumor and non-tumor condi-
tions, and suggests the non invasive technique SSR as a 
simple, useful tool to investigate skin vascular anomalies.
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